Literature DB >> 18789796

Etiology and treatment of macular edema.

Mark W Johnson1.   

Abstract

PURPOSE: To summarize current concepts and recent literature regarding the pathogenesis, clinical substrates, and treatment of macular edema, in light of evolving pharmacologic and surgical approaches to this prevalent cause of vision loss.
DESIGN: Interpretive essay.
METHODS: Review and synthesis of selected recent literature, with interpretation and perspective.
RESULTS: Macular edema occurs in a wide variety of pathologic conditions and represents the final common phenotype of several basic pathophysiologic processes. A variety of pharmacologic agents targeting inflammatory and vasopermeability molecules have been shown to reduce macular edema and improve visual function over the short-term. Vitreous surgery effectively addresses the tractional components of macular edema, where present. Despite recent advances, laser photocoagulation remains the treatment of choice for macular edema associated with nondiffuse patterns of vascular leakage.
CONCLUSIONS: Effective management of macular edema is based on recognizing and addressing the pathogenic factors that are operative in a given disease setting. Although treatment options are expanding with the development of new drugs and surgical procedures, the long-term efficacy and safety of most new approaches have yet to be established in controlled clinical trials.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18789796     DOI: 10.1016/j.ajo.2008.07.024

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  55 in total

1.  Detection of cystoid macular edema with three-dimensional optical coherence tomography versus fluorescein angiography.

Authors:  Yanling Ouyang; Pearse A Keane; Srinivas R Sadda; Alexander C Walsh
Journal:  Invest Ophthalmol Vis Sci       Date:  2010-03-31       Impact factor: 4.799

2.  Novel atypical PKC inhibitors prevent vascular endothelial growth factor-induced blood-retinal barrier dysfunction.

Authors:  Paul M Titchenell; Cheng-Mao Lin; Jason M Keil; Jeffrey M Sundstrom; Charles D Smith; David A Antonetti
Journal:  Biochem J       Date:  2012-09-15       Impact factor: 3.857

3.  Optical coherence tomography analysis of patients with untreated diabetic macular edema.

Authors:  Haiying Chen; Mei Hong Tan; Dustin Pomerleau; Elaine W Chong; Lyndell L Lim; R C Andrew Symons
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2019-12-26       Impact factor: 3.117

Review 4.  [Statement of the Professional Association of German Ophthalmologists (BVA), the German Ophthalmological Society (DOG) and the Retinological Society (RG) on the development, diagnostics and treatment of epiretinal gliosis : Status October 2020].

Authors: 
Journal:  Ophthalmologe       Date:  2021-02       Impact factor: 1.059

Review 5.  [Clinical, morphological and molecular biological characteristics of the aging eye].

Authors:  M R R Böhm; H Thomasen; F Parnitzke; K-P Steuhl
Journal:  Ophthalmologe       Date:  2017-02       Impact factor: 1.059

6.  Should steroids be offered to patients with nonarteritic anterior ischemic optic neuropathy?

Authors:  Andrew G Lee; Valérie Biousse
Journal:  J Neuroophthalmol       Date:  2010-06       Impact factor: 3.042

7.  Fingolimod and macular edema: Pathophysiology, diagnosis, and management.

Authors:  Sudha Cugati; Celia S Chen; Stewart Lake; Andrew W Lee
Journal:  Neurol Clin Pract       Date:  2014-10

Review 8.  Anti-vascular endothelial growth factor therapy for diabetic macular edema.

Authors:  David S Boyer; J Jill Hopkins; Jonathan Sorof; Jason S Ehrlich
Journal:  Ther Adv Endocrinol Metab       Date:  2013-12       Impact factor: 3.565

9.  Vascular endothelial growth factor modulates the function of the retinal pigment epithelium in vivo.

Authors:  Mohammad Dahrouj; Oday Alsarraf; Jake C McMillin; Yueying Liu; Craig E Crosson; Zsolt Ablonczy
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-09       Impact factor: 4.799

10.  The effect of topical sodium diclofenac on macular thickness in diabetic eyes after phacoemulsification: a randomized controlled trial.

Authors:  Morteza Entezari; Alireza Ramezani; Homayon Nikkhah; Mehdi Yaseri
Journal:  Int Ophthalmol       Date:  2016-03-14       Impact factor: 2.031

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.